Clinical Trials Logo

Pharynx Cancer clinical trials

View clinical trials related to Pharynx Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05837221 Recruiting - Clinical trials for Head and Neck Cancer

Microbiome in Head and Neck Squamous Cell Carcinoma

Start date: December 2024
Phase:
Study type: Observational

This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.

NCT ID: NCT05719779 Recruiting - Sleep Apnea Clinical Trials

Tolerance and Benefits of Mandibular Advanced Device for Snoring and Sleep Apnea in Oropharyngeal Cancer.

Ronco-Onco
Start date: February 3, 2023
Phase: N/A
Study type: Interventional

Evaluation of the Tolerance and Benefits of Mandibular Advanced Device (MAD) for Snoring and Sleep Apnea in Patients with Oropharyngeal Cancer (OPC): Mixed Design Study.

NCT ID: NCT04892875 Withdrawn - Clinical trials for Head and Neck Cancer

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

PANTHEoN
Start date: December 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of chemotherapy and radiation in combination with the investigational study drugs zimberelimab (AB122) and etrumadenant (AB928) in subjects with a locally advances head or neck cancer. The study will also ask how the study drugs change the following: - The microbiome that lives in the mouth and on the skin - Immune cells as they respond to a skin wound - Scarring (fibrosis) caused by radiation After completing a screening phase, subjects will be assigned to one of three cohorts: - Cohort 1: Subjects who will receive cisplatin, radiation and zimberelimab followed by zimberelimab only. - Cohort 2: Subjects who will receive cisplatin, radiation, zimberelimab and etrumadenant followed by zimberelimab and etrumadent. - Cohort 3: Subjects who will receive cisplatin and radiation followed by an observation period. All three cohorts will be followed for a 24 months following the conclusion of the chemoradiation.

NCT ID: NCT04028479 Recruiting - Breast Cancer Clinical Trials

The Registry of Oncology Outcomes Associated With Testing and Treatment

ROOT
Start date: May 5, 2021
Phase:
Study type: Observational [Patient Registry]

This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.

NCT ID: NCT03653039 Completed - Larynx Cancer Clinical Trials

Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy

Tritube
Start date: September 12, 2018
Phase: N/A
Study type: Interventional

The investigators compare the ease of intubation between a new ultra-thin endotracheal tube, "Tritube", and a standard endotracheal tube in patients with predictors of difficult laryngoscopy. Furthermore the investigators compare the acceptance of leaving the Tritube in trachea after end of anaesthesia, with the use of a tube exchange catheter.

NCT ID: NCT03479463 Terminated - Larynx Cancer Clinical Trials

Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy

Start date: March 19, 2018
Phase:
Study type: Observational [Patient Registry]

This trial aims to determine if intra-operative use of human dehydrated amnion chorion allograft improves post-operative patient healing outcomes.

NCT ID: NCT00359645 Completed - Oesophageal Cancer Clinical Trials

Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population

Start date: June 21, 2006
Phase: Phase 3
Study type: Interventional

Randomized multicenter trial to assess the impact of a screening program for heavy alcohol drinkers and smokers treated in alcohol addiction clinics on upper aerodigestive tract cancer mortality.

NCT ID: NCT00140556 Completed - Clinical trials for Head and Neck Cancer

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

Start date: August 2005
Phase: Phase 0
Study type: Interventional

Radiotherapy (RT) with concurrent chemotherapy represents the state of the art in curative intent treatment for locally advanced squamous carcinoma of the head and neck. Tumor hypoxia and high levels of angiogenesis (blood vessel formation) are associated with treatment failure. Preclinical models reveal that radiotherapy itself may induce tumor secretion of vascular endothelial growth factor (VEGF). Curability may consequently be reduced by multiple mechanisms. Over-expression of epidermal growth factor receptor (EGFR) also occurs commonly and increases the risk of treatment failure. The addition of EGFR blockade to RT alone increases the chance of a cure. Concurrent VEGF and EGFR blockade could be synergistic with one another and improve the effectiveness of concurrent chemoradiation for advanced head and neck cancer. This study will add angiogenic and epidermal growth factor receptor (EGFR) blockade into an established program of curative intent concurrent chemoradiation for locally advanced head and neck cancer. The safety and effectiveness of delivering the drugs bevacizumab and Tarceva in conjunction with twice daily irradiation and concurrent cisplatin (CDDP) chemotherapy will be determined.